USP22 promotes melanoma and BRAF inhibitor resistance via YAP stabilization

• DOI: 10.3892/ol.2021.12655
• Publication Date: 2021-03-18T12:43:50Z
• Authors: Ying Wei; Ziyun Jiang; Jianfeng Lu
• Keywords: Deubiquitinating enzyme

Yes‑associated protein (YAP) is a conserved transcriptional coactivator that plays key roles in controlling organ size, tumorigenesis and drug resistance. Emerging evidence shows YAP overexpressed associated with resistance to BRAF inhibitor treatment melanoma. However, the mechanism accounting for YAP‑overexpression melanoma largely unknown. The present study characterized ubiquitin‑specific peptidase 22 (USP22) as deubiquitinase abundance biological functions Using western blotting immunohistochemical staining, it was found expression of USP22 cell lines patient samples. Moreover, interacted deubiquitinated prevent turnover. Depletion decreased expression, which turn suppressed proliferation tumorigenesis. Furthermore, overexpression conferred vemurafenib YAP‑dependent manner. Overall, revealed important role USP22/YAP axis resistance, provides rationale target treatment.